Bliss Gvs Pharma LimitedNSE: BLISSGVS

BLISSGVS: Double-digit revenue and profit growth, strong margins, and expansion in global markets

· Issued by Bliss Gvs Pharma Limited

Revenue and net profit saw double-digit growth year-over-year, with strong EBITDA margins and a net-zero debt position. Expansion in regulated and African markets, capacity investments, and digital transformation supported robust performance. Final dividend of ₹1.00 per share recommended.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Company analysis

Earlier from Bliss Gvs Pharma

All Bliss Gvs Pharma news releases